PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774870
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774870
Global Gastrointestinal Bleeding Treatment Market to Reach US$1.2 Billion by 2030
The global market for Gastrointestinal Bleeding Treatment estimated at US$845.9 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Endoscopic Hemostatic Devices, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$704.8 Million by the end of the analysis period. Growth in the Closure Devices segment is estimated at 8.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$230.5 Million While China is Forecast to Grow at 9.0% CAGR
The Gastrointestinal Bleeding Treatment market in the U.S. is estimated at US$230.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$238.8 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.
Global Gastrointestinal Bleeding Treatment Market - Key Trends & Drivers Summarized
Why Is Gastrointestinal Bleeding Treatment Becoming More Advanced and Effective?
Gastrointestinal (GI) bleeding treatment has evolved significantly in recent years, driven by advancements in diagnostic techniques, minimally invasive procedures, and targeted pharmacological therapies. GI bleeding, which can occur in the upper or lower digestive tract, is a serious medical condition that requires prompt diagnosis and intervention to prevent life-threatening complications. The most common causes include peptic ulcers, diverticulosis, inflammatory bowel disease (IBD), esophageal varices, and colorectal cancer.
The increasing prevalence of GI disorders, coupled with the aging global population, has heightened the demand for effective treatment solutions. Endoscopic hemostasis techniques, such as clip placement, argon plasma coagulation (APC), and injection therapy, have become the gold standard for controlling active bleeding in most cases. Additionally, the integration of artificial intelligence (AI) in endoscopic imaging has enhanced the early detection of bleeding sources, improving patient outcomes. As healthcare providers continue to adopt advanced treatment modalities, the landscape of GI bleeding management is shifting toward faster, safer, and more efficient interventions.
Which Treatment Modalities Are Driving Innovation in Gastrointestinal Bleeding Management?
The management of gastrointestinal bleeding has been revolutionized by a combination of endoscopic, pharmacological, and surgical interventions. Endoscopic procedures remain the primary treatment approach for acute GI bleeding, with techniques such as thermal coagulation, band ligation, and hemostatic spray technology providing immediate hemostasis. Capsule endoscopy and deep enteroscopy have also enhanced the ability to diagnose and treat obscure GI bleeding in the small intestine, an area previously difficult to access with conventional endoscopy.
Pharmacological treatments, including proton pump inhibitors (PPIs), vasoactive drugs, and tranexamic acid, play a crucial role in preventing rebleeding and managing underlying conditions. In severe cases, interventional radiology procedures such as transarterial embolization (TAE) are utilized to control bleeding when endoscopic methods fail. For patients with refractory GI bleeding, surgical intervention, including partial colectomy or gastrectomy, may be required. The growing adoption of combination therapy, integrating endoscopic and pharmacological treatments, has improved overall patient survival rates and reduced hospitalization costs.
How Are Technological Advancements Enhancing Gastrointestinal Bleeding Treatment?
Recent technological advancements have significantly improved the diagnosis, treatment, and prevention of gastrointestinal bleeding. AI-assisted endoscopy is one of the most transformative innovations, enabling real-time image analysis and automated detection of bleeding lesions. This technology enhances physician accuracy, reduces procedure times, and improves early detection of high-risk lesions. Additionally, the development of advanced hemostatic agents, including sprayable biologics and bioabsorbable hemostats, has expanded treatment options for complex bleeding cases.
Another breakthrough is the use of robotic-assisted endoscopic procedures, which offer greater precision and maneuverability in treating difficult-to-reach areas of the gastrointestinal tract. Smart capsule endoscopy has also gained traction, allowing for non-invasive visualization of the small intestine without the need for sedation or radiation exposure. Furthermore, advances in gene therapy and regenerative medicine are being explored to treat chronic GI conditions that predispose patients to recurrent bleeding episodes. These technological innovations are reshaping the future of GI bleeding management, enhancing both patient outcomes and healthcare efficiency.
What Factors Are Fueling the Growth of the Gastrointestinal Bleeding Treatment Market?
The growth in the gastrointestinal bleeding treatment market is driven by several factors, including the rising prevalence of GI disorders, increasing adoption of advanced endoscopic techniques, and the expansion of minimally invasive treatment options. The aging population, particularly in developed nations, has led to a higher incidence of peptic ulcers, diverticulosis, and esophageal varices, all of which contribute to GI bleeding cases.
Technological innovations, such as AI-assisted endoscopy, robotic procedures, and hemostatic biomaterials, have enhanced the effectiveness of GI bleeding treatment, prompting greater adoption by healthcare providers. The expansion of outpatient and ambulatory surgical centers has also increased patient access to minimally invasive procedures, reducing the need for hospitalization. Additionally, government initiatives promoting early screening and diagnostic programs for colorectal cancer and GI disorders have further fueled market growth. As the demand for effective and less invasive GI bleeding treatments continues to rise, the market is expected to expand, driven by continuous advancements in medical technology and patient-centered care solutions.
SCOPE OF STUDY:
The report analyzes the Gastrointestinal Bleeding Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product (Endoscopic Hemostatic Devices, Closure Devices, Other Products); GI Tract Division (Upper GI Tract, Lower GI Tract); Onset (Acute Onset, Chronic Onset); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Users)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 48 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.